Logo image of NCNA

NUCANA PLC-ADR (NCNA) Stock Fundamental Analysis

NASDAQ:NCNA - Nasdaq - US67022C2052 - ADR - Currency: USD

0.0549  -0.01 (-8.5%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NCNA. NCNA was compared to 555 industry peers in the Biotechnology industry. NCNA has a bad profitability rating. Also its financial health evaluation is rather negative. NCNA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NCNA had negative earnings in the past year.
In the past year NCNA has reported a negative cash flow from operations.
In the past 5 years NCNA always reported negative net income.
In the past 5 years NCNA always reported negative operating cash flow.
NCNA Yearly Net Income VS EBIT VS OCF VS FCFNCNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

NCNA has a worse Return On Assets (-126.13%) than 82.52% of its industry peers.
With a Return On Equity value of -350.55%, NCNA is not doing good in the industry: 74.59% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -126.13%
ROE -350.55%
ROIC N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
NCNA Yearly ROA, ROE, ROICNCNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

NCNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NCNA Yearly Profit, Operating, Gross MarginsNCNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for NCNA has been increased compared to 1 year ago.
The number of shares outstanding for NCNA has been increased compared to 5 years ago.
NCNA has a better debt/assets ratio than last year.
NCNA Yearly Shares OutstandingNCNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
NCNA Yearly Total Debt VS Total AssetsNCNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

NCNA has an Altman-Z score of -22.62. This is a bad value and indicates that NCNA is not financially healthy and even has some risk of bankruptcy.
NCNA has a Altman-Z score of -22.62. This is amonst the worse of the industry: NCNA underperforms 86.85% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that NCNA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, NCNA is in line with its industry, outperforming 40.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -22.62
ROIC/WACCN/A
WACCN/A
NCNA Yearly LT Debt VS Equity VS FCFNCNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 1.25 indicates that NCNA should not have too much problems paying its short term obligations.
The Current ratio of NCNA (1.25) is worse than 84.68% of its industry peers.
A Quick Ratio of 1.25 indicates that NCNA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.25, NCNA is doing worse than 83.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.25
NCNA Yearly Current Assets VS Current LiabilitesNCNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.69% over the past year.
EPS 1Y (TTM)97.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NCNA will show a small growth in Earnings Per Share. The EPS will grow by 2.20% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCNA Yearly Revenue VS EstimatesNCNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2029 2030 2031 2032 50M 100M 150M
NCNA Yearly EPS VS EstimatesNCNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NCNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NCNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NCNA Price Earnings VS Forward Price EarningsNCNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NCNA Per share dataNCNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

NCNA's earnings are expected to grow with 20.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y20.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NCNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUCANA PLC-ADR

NASDAQ:NCNA (7/2/2025, 10:51:10 AM)

0.0549

-0.01 (-8.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-02 2025-06-02/amc
Earnings (Next)08-13 2025-08-13/amc
Inst Owners5.61%
Inst Owner Change-39.7%
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap332.53K
Analysts82.5
Price Target25.5 (46348.09%)
Short Float %76.16%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.12
EV/EBITDA N/A
EPS(TTM)-7.57
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-3.77
FCFYN/A
OCF(TTM)-3.71
OCFYN/A
SpS0
BVpS0.95
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -126.13%
ROE -350.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.25
Altman-Z -22.62
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.01%
Cap/Depr(5y)101.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.46%
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.29%
OCF growth 3YN/A
OCF growth 5YN/A